Corcept Therapeutics Inc - Understand $cort stock

$CORT Market Cap: $5.741 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$628.6M

TTM

Gross Margin

98.44%

TTM

Net Earnings

$141.8M

TTM

Current Assets

$467.0M

Q3 2024

Current Liabilities

$126.2M

Q3 2024

Current Ratio

369.98%

Q3 2024

Total Assets

$784.3M

Q3 2024

Total Liabilities

$145.4M

Q3 2024

Book Value

$638.8M

Q3 2024

Cash

$137.3M

Q3 2024

P/E

40.48

Nov 14, 2024 EST

Free Cash Flow

$118.8M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000
Revenue	$482.4M	$401.9M	$366.0M	$353.9M	$306.5M	$251.2M	$159.2M	$81.32M	$50.29M	$26.55M	$10.36M	$3.307M	$0.00	$0.00	$0.00	$200.0K	$500.0K	$300.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	20.04%	9.8%	3.42%	15.46%	21.99%	57.82%	95.77%	61.72%	89.39%	156.36%	213.18%				-100.0%	-60.0%	66.67%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000
Revenue	$482.4M	$401.9M	$366.0M	$353.9M	$306.5M	$251.2M	$159.2M	$81.32M	$50.29M	$26.55M	$10.36M	$3.307M	$0.00	$0.00	$0.00	$200.0K	$500.0K	$300.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue	$6.481M	$5.385M	$5.281M	$5.582M	$5.504M	$5.215M	$3.554M	$2.058M	$1.361M	$882.0K	$143.0K	$91.00K
Gross Profit	$475.9M	$396.5M	$360.7M	$348.3M	$301.0M	$246.0M	$155.6M	$79.26M	$48.93M	$25.67M	$10.21M	$3.216M
Gross Profit Margin	98.66%	98.66%	98.56%	98.42%	98.2%	97.92%	97.77%	97.47%	97.29%	96.68%	98.62%	97.25%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000
Selling, General & Admin	$184.3M	$152.8M	$122.4M	$105.3M	$100.4M	$81.29M	$62.42M	$45.24M	$36.95M	$34.92M	$31.24M	$25.41M	$11.33M	$8.488M	$4.300M	$4.400M	$4.000M	$5.000M	$4.100M	$4.500M	$1.700M	$5.500M	$2.600M	$600.0K
YoY Change	20.55%	24.92%	16.17%	4.95%	23.46%	30.24%	37.97%	22.44%	5.82%	11.77%	22.92%	124.29%	33.49%	97.4%	-2.27%	10.0%	-20.0%	21.95%	-8.89%	164.71%	-69.09%	111.54%	333.33%	200.0%
% of Gross Profit	38.72%	38.55%	33.92%	30.24%	33.34%	33.04%	40.1%	57.08%	75.52%	136.02%	305.85%	790.24%
Research & Development	$184.4M	$131.0M	$113.9M	$114.8M	$89.02M	$75.25M	$40.38M	$23.84M	$15.42M	$18.37M	$20.47M	$14.07M	$21.00M	$18.95M	$16.00M	$15.50M	$8.700M	$20.80M	$17.10M	$11.60M	$8.200M	$13.30M	$5.400M	$1.300M
YoY Change	40.74%	15.04%	-0.78%	28.92%	18.3%	86.37%	69.33%	54.64%	-16.07%	-10.25%	45.45%	-32.98%	10.83%	18.43%	3.23%	78.16%	-58.17%	21.64%	47.41%	41.46%	-38.35%	146.3%	315.38%	1200.0%
% of Gross Profit	38.74%	33.04%	31.57%	32.95%	29.58%	30.58%	25.94%	30.08%	31.52%	71.57%	200.41%	437.62%
Depreciation & Amortization	$577.0K	$782.0K	$1.072M	$525.0K	$703.0K	$236.0K	$106.0K	$87.00K	$155.0K	$141.0K	$74.00K	$27.00K	$3.000K	$6.000K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-26.21%	-27.05%	104.19%	-25.32%	197.88%	122.64%	21.84%	-43.87%	9.93%	90.54%	174.07%	800.0%	-50.0%
% of Gross Profit	0.12%	0.2%	0.3%	0.15%	0.23%	0.1%	0.07%	0.11%	0.32%	0.55%	0.72%	0.84%
Operating Expenses	$368.6M	$283.8M	$236.2M	$220.1M	$189.4M	$156.5M	$102.8M	$69.08M	$52.37M	$53.29M	$51.85M	$39.58M	$32.33M	$27.44M	$20.30M	$19.90M	$12.70M	$25.90M	$21.20M	$16.00M	$10.00M	$18.80M	$8.000M	$1.900M
YoY Change	29.87%	20.16%	7.33%	16.22%	20.98%	52.28%	48.79%	31.92%	-1.73%	2.77%	31.01%	22.41%	17.84%	35.16%	2.01%	56.69%	-50.97%	22.17%	32.5%	60.0%	-46.81%	135.0%	321.05%	533.33%
Operating Profit	$107.3M	$112.6M	$124.5M	$128.2M	$111.6M	$89.50M	$52.86M	$10.18M	-$3.443M	-$27.62M	-$41.50M	-$36.27M	-$32.33M	-$27.44M
YoY Change	-4.75%	-9.51%	-2.91%	14.87%	24.71%	69.32%	419.26%	-395.64%	-87.53%	-33.44%	14.4%	12.19%	17.84%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000
Interest Expense	$17.28M	$3.557M	$529.0K	$3.400M	$5.100M	$2.700M	-$500.0K	-$1.900M	-$3.000M	-$3.800M	-$4.500M	-$1.800M	$0.00	$700.0K	$100.0K	-$400.0K	$700.0K	$700.0K	$1.100M	$500.0K	$200.0K	$300.0K	$600.0K	$100.0K
YoY Change	385.66%	572.4%	-84.44%	-33.33%	88.89%	-640.0%	-73.68%	-36.67%	-21.05%	-15.56%	150.0%		-100.0%	600.0%	-125.0%	-157.14%	0.0%	-36.36%	120.0%	150.0%	-33.33%	-50.0%	500.0%
% of Operating Profit	16.1%	3.16%	0.42%	2.65%	4.57%	3.02%	-0.95%	-18.67%
Other Income/Expense, Net	$17.28M	$3.557M	$529.0K				$400.0K	-$100.0K
YoY Change	385.66%	572.4%					-500.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000
Pretax Income	$124.6M	$116.2M	$125.0M	$131.6M	$116.7M	$92.15M	$52.81M	$8.140M	-$6.408M	-$31.40M	-$46.00M	-$38.00M	-$32.40M	-$26.00M	-$20.20M	-$20.10M	-$11.60M	-$24.90M	-$20.10M	-$15.50M	-$9.800M	-$18.50M	-$7.500M	-$1.800M
YoY Change	7.2%	-7.05%	-5.01%	12.79%	26.61%	74.51%	548.72%	-227.03%	-79.59%	-31.74%	21.05%	17.28%	24.62%	28.71%	0.5%	73.28%	-53.41%	23.88%	29.68%	58.16%	-47.03%	146.67%	316.67%	500.0%
Income Tax	$18.42M	$14.77M	$12.49M	$25.59M	$22.50M	$16.74M	-$76.32M	$0.00	$0.00	$0.00				$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income	14.79%	12.71%	9.99%	19.45%	19.28%	18.17%	-144.52%	0.0%
Net Earnings	$106.1M	$101.4M	$112.5M	$106.0M	$94.18M	$75.41M	$129.1M	$8.140M	-$6.408M	-$31.38M	-$46.01M	-$38.05M	-$32.35M	-$25.97M	-$20.20M	-$20.10M	-$11.60M	-$24.90M	-$20.10M	-$15.50M	-$9.800M	-$18.50M	-$7.500M	-$1.800M
YoY Change	4.66%	-9.86%	6.13%	12.56%	24.89%	-41.6%	1486.27%	-227.03%	-79.58%	-31.79%	20.93%	17.6%	24.6%	28.54%	0.5%	73.28%	-53.41%	23.88%	29.68%	58.16%	-47.03%	146.67%	316.67%	500.0%
Net Earnings / Revenue	22.0%	25.24%	30.74%	29.96%	30.73%	30.01%	81.11%	10.01%	-12.74%	-118.2%	-444.25%	-1150.53%				-10050.0%	-2320.0%	-8300.0%
Basic Earnings Per Share	$1.02	$0.95	$0.97	$0.92	$0.82	$0.65	$1.14	$0.07	-$0.06
Diluted Earnings Per Share	$0.94	$0.87	$0.89	$0.85	$0.77	$0.60	$1.04	$0.07	-$0.06	-$310.9K	-$460.9K	-$408.6K	-$389.0K	-$380.7K	-$385.5K	-$430.4K	-$338.2K	-$1.092M	-$889.4K	-$842.4K	-$1.210M	-$2.761M	-$1.250M	-$321.4K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000
Cash & Short-Term Investments	$368.2M	$431.7M	$223.5M	$440.7M	$276.0M	$206.8M	$88.70M	$51.50M	$40.40M	$24.20M	$54.90M	$93.00M	$39.60M	$24.60M	$23.90M	$18.30M	$17.40M	$9.500M	$29.10M	$37.40M	$11.60M	$21.50M	$23.00M	$1.000M
YoY Change	-14.7%	93.11%	-49.28%	59.67%	33.46%	133.15%	72.23%	27.48%	66.94%	-55.92%	-40.97%	134.85%	60.98%	2.93%	30.6%	5.17%	83.16%	-67.35%	-22.19%	222.41%	-46.05%	-6.52%	2200.0%
Cash & Equivalents	$135.6M	$66.33M	$77.62M	$76.20M	$31.30M	$41.60M	$31.10M	$51.50M	$40.40M	$24.20M	$52.90M	$93.00M	$39.60M	$24.60M	$23.90M	$14.70M	$11.40M	$8.900M	$3.800M	$5.900M	$10.10M	$18.40M	$23.00M	$1.000M
Short-Term Investments	$232.7M	$365.3M	$145.9M	$364.5M	$244.7M	$165.1M	$57.70M								$0.00	$3.600M	$5.900M	$600.0K	$25.30M	$31.50M	$1.500M	$3.100M
Other Short-Term Assets	$41.56M	$30.42M	$10.32M	$6.700M	$6.000M	$7.700M	$2.700M	$2.000M	$600.0K	$1.400M	$900.0K	$600.0K	$100.0K	$400.0K	$600.0K	$1.300M	$300.0K	$300.0K	$400.0K	$800.0K	$200.0K	$200.0K	$700.0K	$0.00
YoY Change	36.61%	194.95%	53.96%	11.67%	-22.08%	185.19%	35.0%	233.33%	-57.14%	55.56%	50.0%	500.0%	-75.0%	-33.33%	-53.85%	333.33%	0.0%	-25.0%	-50.0%	300.0%	0.0%	-71.43%
Inventory	$7.730M	$6.100M	$4.988M	$4.900M	$5.400M	$4.700M	$4.600M	$2.300M	$1.700M	$1.200M	$1.100M	$900.0K
Prepaid Expenses
Receivables	$41.12M	$31.06M	$27.63M	$26.20M	$19.90M	$17.60M	$15.30M	$9.900M	$6.200M	$3.300M	$1.400M	$600.0K
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$12.90M	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$458.6M	$499.3M	$266.5M	$478.5M	$307.4M	$236.8M	$124.2M	$65.70M	$49.00M	$30.20M	$58.30M	$95.10M	$39.80M	$25.00M	$24.40M	$19.60M	$17.70M	$9.800M	$29.50M	$38.20M	$11.70M	$21.70M	$23.60M	$1.000M
YoY Change	-8.14%	87.36%	-44.31%	55.66%	29.81%	90.66%	89.04%	34.08%	62.25%	-48.2%	-38.7%	138.94%	59.2%	2.46%	24.49%	10.73%	80.61%	-66.78%	-22.77%	226.5%	-46.08%	-8.05%	2260.0%
Property, Plant & Equipment	$315.0K	$1.776M	$1.516M	$4.200M	$4.500M	$700.0K	$500.0K	$200.0K	$100.0K	$200.0K	$200.0K	$200.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$100.0K	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-82.26%	17.15%	-63.9%	-6.67%	542.86%	40.0%	150.0%	100.0%	-50.0%	0.0%	0.0%							-100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$57.18M	$4.947M	$112.3M	$36.20M	$39.40M	$0.00	$15.30M										$0.00	$0.00	$500.0K	$9.500M
YoY Change	1055.77%	-95.59%	210.16%	-8.12%		-100.0%												-100.0%	-94.74%
Other Assets	$105.4M	$77.45M	$43.50M	$52.90M	$61.10M	$74.20M	$80.60M	$2.900M	$2.800M	$4.200M	$4.600M	$4.000M	$0.00	$100.0K	$100.0K	$200.0K	$100.0K	$100.0K	$100.0K	$0.00	$0.00	$0.00	$600.0K	$0.00
YoY Change	36.07%	78.06%	-17.77%	-13.42%	-17.65%	-7.94%	2679.31%	3.57%	-33.33%	-8.7%	15.0%		-100.0%	0.0%	-50.0%	100.0%	0.0%	0.0%				-100.0%
Total Long-Term Assets	$162.9M	$84.18M	$157.3M	$93.20M	$104.9M	$74.90M	$96.30M	$3.100M	$2.900M	$4.400M	$4.800M	$4.100M	$0.00	$100.0K	$100.0K	$200.0K	$0.00	$100.0K	$700.0K	$9.600M	$100.0K	$100.0K	$700.0K	$0.00
YoY Change	93.5%	-46.48%	68.77%	-11.15%	40.05%	-22.22%	3006.45%	6.9%	-34.09%	-8.33%	17.07%		-100.0%	0.0%	-50.0%		-100.0%	-85.71%	-92.71%	9500.0%	0.0%	-85.71%
Total Assets	$621.5M	$583.4M	$423.8M	$571.7M	$412.3M	$311.7M	$220.5M	$68.80M	$51.90M	$34.60M	$63.10M	$99.20M	$39.80M	$25.10M	$24.50M	$19.80M	$17.70M	$9.900M	$30.20M	$47.80M	$11.80M	$21.80M	$24.30M	$1.000M
YoY Change
Accounts Payable	$17.40M	$11.98M	$6.908M	$10.60M	$7.500M	$8.300M	$8.600M	$2.300M	$1.300M	$1.900M	$2.400M	$3.800M	$3.600M	$800.0K	$1.300M	$1.300M	$1.100M	$900.0K	$500.0K	$600.0K	$300.0K	$800.0K	$900.0K	$100.0K
YoY Change	45.26%	73.36%	-34.83%	41.33%	-9.64%	-3.49%	273.91%	76.92%	-31.58%	-20.83%	-36.84%	5.56%	350.0%	-38.46%	0.0%	18.18%	22.22%	80.0%	-16.67%	100.0%	-62.5%	-11.11%	800.0%
Accrued Expenses	$85.30M	$60.43M	$40.12M	$36.90M	$30.80M	$25.80M	$21.00M	$10.40M	$4.400M	$2.200M	$4.600M	$1.900M	$1.400M	$3.000M	$1.100M	$1.500M	$1.500M	$2.400M	$2.700M	$1.000M	$700.0K	$700.0K	$600.0K	$300.0K
YoY Change	41.16%	50.61%	8.73%	19.81%	19.38%	22.86%	101.92%	136.36%	100.0%	-52.17%	142.11%	35.71%	-53.33%	172.73%	-26.67%	0.0%	-37.5%	-11.11%	170.0%	42.86%	0.0%	16.67%	100.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due							$0.00	$14.70M	$15.00M	$9.400M	$5.700M	$2.700M		$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00			$0.00	$900.0K
YoY Change							-100.0%	-2.0%	59.57%	64.91%	111.11%												-100.0%
Total Short-Term Liabilities	$104.5M	$72.49M	$47.54M	$47.50M	$38.80M	$35.60M	$29.60M	$27.40M	$20.90M	$13.60M	$12.70M	$8.400M	$5.000M	$3.900M	$2.400M	$2.900M	$3.000M	$3.500M	$3.500M	$1.800M	$1.000M	$1.500M	$1.400M	$1.200M
YoY Change	44.16%	52.48%	0.09%	22.42%	8.99%	20.27%	8.03%	31.1%	53.68%	7.09%	51.19%	68.0%	28.21%	62.5%	-17.24%	-3.33%	-14.29%	0.0%	94.44%	80.0%	-33.33%	7.14%	16.67%
Long-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$12.50M	$24.50M	$29.30M	$29.00M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$500.0K	$500.0K	$500.0K	$0.00
YoY Change								-100.0%	-48.98%	-16.38%	1.03%									-100.0%	0.0%	0.0%
Other Long-Term Liabilities	$10.31M	$9.097M	$409.0K	$900.0K	$2.300M	$200.0K
YoY Change	13.3%	2124.21%	-54.56%	-60.87%	1050.0%
Total Long-Term Liabilities	$10.31M	$9.097M	$409.0K	$900.0K	$2.300M	$200.0K	$0.00	$0.00	$12.50M	$24.50M	$29.30M	$29.00M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$500.0K	$500.0K	$500.0K	$0.00
YoY Change	13.3%	2124.21%	-54.56%	-60.87%	1050.0%			-100.0%	-48.98%	-16.38%	1.03%									-100.0%	0.0%	0.0%
Total Liabilities	$114.8M	$81.59M	$47.95M	$48.40M	$41.10M	$35.80M	$29.60M	$27.40M	$33.40M	$38.00M	$42.10M	$37.40M	$5.000M	$3.900M	$2.400M	$2.900M	$3.000M	$3.500M	$3.600M	$1.800M	$1.500M	$2.000M	$1.900M	$1.200M
YoY Change	40.72%	70.15%	-0.93%	17.76%	14.8%	20.95%	8.03%	-17.96%	-12.11%	-9.74%	12.57%	648.0%	28.21%	62.5%	-17.24%	-3.33%	-14.29%	-2.78%	100.0%	20.0%	-25.0%	5.26%	58.33%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Basic Shares Outstanding	103.6M shares	106.8M shares	115.7M shares	115.4M shares	114.3M shares	115.3M shares	113.5M shares	110.6M shares	106.9M	101.0M
Diluted Shares Outstanding	111.7M shares	116.0M shares	126.0M shares	124.2M shares	122.6M shares	126.7M shares	124.5M shares	116.1M shares	106.9M	101.0M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $5.7406 Billion

About Corcept Therapeutics Inc

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company. The company is headquartered in Menlo Park, California and currently employs 352 full-time employees. The company went IPO on 2004-04-15. The firm operates through the discovery, development and commercialization of the pharmaceutical products segment. The firm has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.

Industry: Pharmaceutical Preparations Peers: Arvinas Inc Pacira Biosciences Inc Elanco Animal Health Inc Harmony Biosciences Holdings Inc Intra-Cellular Therapies Inc Johnson & Johnson Organon & Co Prestige Consumer Healthcare Inc Viatris Inc